Xencor, Inc. $XNCR Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC decreased its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 47.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,566 shares of the biopharmaceutical company’s stock after selling 60,779 shares during the period. SG Americas Securities LLC owned about 0.09% of Xencor worth $815,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC acquired a new position in Xencor during the fourth quarter worth $81,000. Tower Research Capital LLC TRC grew its position in shares of Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 3,018 shares during the period. E Fund Management Co. Ltd. purchased a new stake in shares of Xencor during the second quarter worth about $79,000. NorthCrest Asset Manangement LLC purchased a new stake in shares of Xencor during the fourth quarter worth about $149,000. Finally, Norges Bank acquired a new position in shares of Xencor during the 4th quarter worth about $175,000.

Xencor Price Performance

Shares of Xencor stock opened at $15.00 on Monday. The firm has a market cap of $1.11 billion, a PE ratio of -6.55 and a beta of 0.86. Xencor, Inc. has a 52 week low of $6.92 and a 52 week high of $18.69. The business’s fifty day simple moving average is $12.59 and its 200-day simple moving average is $12.77.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.96). Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. The company had revenue of $4.52 million during the quarter, compared to analysts’ expectations of $27.86 million. During the same quarter last year, the firm posted ($0.66) earnings per share. The firm’s quarterly revenue was down 86.2% on a year-over-year basis. As a group, equities analysts expect that Xencor, Inc. will post -3.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

XNCR has been the topic of several research analyst reports. Wall Street Zen cut Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Wednesday, June 24th. Zacks Research cut shares of Xencor from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 6th. Finally, JPMorgan Chase & Co. increased their target price on shares of Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Monday, May 11th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Xencor presently has an average rating of “Hold” and an average target price of $24.50.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.